Skip to main content
Clinical Trials/NCT01307384
NCT01307384
Active, not recruiting
Not Applicable

Prospective Post Market Clinical Follow-Up Study of the Continuum Metal on Polyethylene Acetabular System

Zimmer Biomet2 sites in 1 country165 target enrollmentMarch 29, 2011

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Avascular Necrosis
Sponsor
Zimmer Biomet
Enrollment
165
Locations
2
Primary Endpoint
Survivorship
Status
Active, not recruiting
Last Updated
10 months ago

Overview

Brief Summary

This is a prospective, multi-center, non-randomized, non-controlled study designed to obtain survival and outcome data on the Continuum Metal on Polyethylene Acetabular System when used in primary total hip arthroplasty.

Detailed Description

The safety and performance of the Continuum Metal on Polyethylene Acetabular System will be confirmed by the assessment of survival and outcome data. Assessments will include standard scoring systems, radiographs and adverse event records. Data will be used to monitor pain, mobility, and survivorship of the Continuum Metal on Polyethylene Acetabular system in primary total hip arthroplasty. Metal ion (cobalt, chromium and titanium) and renal function (BUN, Creatinine and GFR) levels will be analyzed for a subset of the enrolled study subjects.

Registry
clinicaltrials.gov
Start Date
March 29, 2011
End Date
December 2027
Last Updated
10 months ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • The patient is:
  • A prisoner
  • Mentally incompetent or unable to understand what participation in the study entails
  • A known alcohol or drug abuser
  • Anticipated to be non-compliant
  • The patient has a neuromuscular disorder, vascular disorder or other conditions that could contribute to prosthesis instability, prosthesis fixation failure or complications in postoperative care.
  • The patient has a neurologic condition in the ipsilateral or contralateral limb which affects lower limb function.
  • The patient has a diagnosed systemic disease that could affect his/her safety or the study outcome.
  • The patient is known to be pregnant.
  • The patient is unwilling or unable to give consent or to comply with the follow-up program.

Outcomes

Primary Outcomes

Survivorship

Time Frame: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

Based on removal or intended removal of the device and determined using the Kaplan-Meier method.

Safety / Adverse Events

Time Frame: Surgery, 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

Safety will be evaluated by monitoring the frequency and incidence of device related adverse events or unanticipated adverse device effects in investigational subjects.

Secondary Outcomes

  • Pain and Function / OHS(6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year)
  • Health Status / Radiographic Parameters(6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year)
  • Pain and Function / HHS(6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year)
  • Health Status / SF-12(6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year)

Study Sites (2)

Loading locations...

Similar Trials